BMS Plans Appeal After Sandoz And Teva Eliminate UK Eliquis Patent

UK Ruling Saw Local Counterpart Of European Apixaban Patent Declared Invalid

While Teva and Sandoz have succeeded in having a UK court invalidate a patent and SPC protecting BMS’ Eliquis (apixaban), the originator is planning an appeal against the decision. Meanwhile, further litigation is proceeding over a separate family of Eliquis formulation patents.

UK law litigation court ruling gavel legal case appeal
Apixaban has this month been the subject of a decision, an appeal and further litigation • Source: Alexey Panferov / Alamy Stock Photo

Bristol Myers Squibb has responded swiftly to a UK ruling that invalidated a patent protecting the Eliquis (apixaban) anticoagulant that it developed with Pfizer, with the originator pledging to appeal against the decision involving Sandoz and Teva at the same time as litigation continues over a separate family of apixaban formulation patents.

On 7 April, the England and Wales High Court’s Patents Court ruled that apixaban’s European Patent (UK) 1,427,415 B1...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Legal & IP

  • ADHD

    This is regarding ADHD.

  • GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

     
    • By 

    In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

  • MPP Finds Three More Partners On Key Hepatitis C Treatment

     
    • By 

    The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

  • Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

     
    • By 

    Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin